Aimei Health Technology Co., Ltd. is a Cayman Islands-incorporated special purpose acquisition company (SPAC) formed to identify and execute a merger or business combination with an operating healthcare company, with an initial focus on small-cap biopharmaceutical, medical device, or diagnostics businesses in North America, Europe, and Asia-Pacific. The company has entered into a definitive business combination agreement with United Hydrogen Group Inc. and operates with capital raised through its initial public offering held in a trust account restricted to U.S. Treasury instruments and qualified money market funds. The company's continued operations are contingent upon completing its business combination within a specified timeframe; if no combination is consummated, it must liquidate and return capital to public shareholders.